STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment
STRO-001, Sutro Biopharma’s investigational therapy for multiple…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted…
Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals
Among those with blood cancers — including myeloma, lymphoma,…
FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia
The U.S. Food and Drug Administration (FDA) has approved…
Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma
A combination of Oncolytics Biotech’s investigational therapy…
Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved…
